EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Adherence to Objective Therapeutic Monitoring and Outcomes in Patients with Inflammatory Bowel Disease with Adalimumab Treatment. A Real-world Prospective Study

Panu Wetwittayakhlang, Petra A Golovics, Alex Al Khoury, Elie Ganni, Gustavo Drügg Hahn, Albert Cohen, Jonathan Wyse, Marc Bradette, Talat Bessissow, Waqqas Afif, Gary Wild, Alain Bitton und 1 weitere

Journal of Gastrointestinal and Liver Diseases · 16.12.2022 · 31 (4) · 403-410

DOI: 10.15403/jgld-4375 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, online erschienen am 16.12.2022. Verfasst von Panu Wetwittayakhlang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada; Gastroenterology and Hepatology Unit, Divisio…. Hauptthemen laut MEDLINE: Adalimumab, Colitis, Ulcerative, Crohn Disease, Patient Compliance. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: Objective monitoring and effective early treatment using a treat-to-target approach are key to improving therapeutic outcomes in IBD patients. This study aimed to assess adherence to objective monitoring (clinical, biomarkers, and endoscopy) and its impact on clinical outcomes.

Methods

A prospective, multicenter study included consecutive IBD patients starting on adalimumab therapy between January 2019 and December 2020. Disease activity, assessed by the Harvey-Bradshaw index (HBI), partial Mayo, C-reactive protein (CRP), fecal calprotectin (FCAL), and endoscopy were evaluated at adalimumab initiation and 3, 6, 9 and 12 months. Therapeutic drug monitoring, changes in treatment, drug sustainability, and clinical outcomes were assessed.

Results

104 IBD patients were enrolled (78.8% CD, median age 34.3 years, disease duration 9 years). During the 12 months follow-up, high adherence to clinical activity assessment was observed in both CD (81.3%- 87.7%) and UC patients (76.5-90.9%). CRP measurement decreased over time in both CD (37.3%-54.9%) and UC (29.4%-50.0%). The adherence to serial FCAL monitoring was low in CD (22.7-31.3%) and UC patients (17.6-56.0%). UC patients had higher adherence to early endoscopic assessment (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabColitis, UlcerativeCrohn DiseasePatient ComplianceDrug MonitoringAdultHumansBiomarkersC-Reactive ProteinEndoscopy, GastrointestinalLeukocyte L1 Antigen ComplexProspective StudiesRemission Induction

Substanzen

AdalimumabBiomarkersC-Reactive ProteinLeukocyte L1 Antigen Complex

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada; Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla Univers…
  • Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada; Department of Gastroenterology, Hungarian Defence Forces, Medical Centre, Budapest, Hungary. golovics.petra@gmail.c…
  • Division of Gastroenterology, University of Florida- Jacksonville, Florida, USA. alexkhoury88@gmail.com.
  • Division of Internal Medicine, McGill University Health Centre, Montreal, Quebec, Canada. elie.ganni@mail.mcgill.ca.
  • Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada; Universidade Federal do Rio Grande do Sul, School of Medicine, Graduate Course Sciences in Gastroenterology and Hep…
  • Division of Gastroenterology, Jewish General Hospital, Montreal, Canada. albert.cohen@mcgill.ca.

Zitieren

APA

Wetwittayakhlang, P., Golovics, P. A., Khoury, A. A., Ganni, E., Hahn, G. D., Cohen, A., Wyse, J., Bradette, M., Bessissow, T., Afif, W., Wild, G., Bitton, A., & Lakatos, P. L. (2022). Adherence to Objective Therapeutic Monitoring and Outcomes in Patients with Inflammatory Bowel Disease with Adalimumab Treatment. A Real-world Prospective Study. Journal of Gastrointestinal and Liver Diseases, 31(4), 403-410. https://doi.org/10.15403/jgld-4375

Vancouver

Wetwittayakhlang P, Golovics PA, Khoury AA, Ganni E, Hahn GD, Cohen A, et al. Adherence to Objective Therapeutic Monitoring and Outcomes in Patients with Inflammatory Bowel Disease with Adalimumab Treatment. A Real-world Prospective Study. Journal of Gastrointestinal and Liver Diseases. 2022;31(4):403-410. doi:10.15403/jgld-4375

BibTeX
@article{Wetwittayakhlang2022,
  author = {Wetwittayakhlang, Panu and Golovics, Petra A and Khoury, Alex Al and Ganni, Elie and Hahn, Gustavo Drügg and Cohen, Albert and Wyse, Jonathan and Bradette, Marc and Bessissow, Talat and Afif, Waqqas and Wild, Gary and Bitton, Alain and Lakatos, Peter Laszlo},
  title = {Adherence to Objective Therapeutic Monitoring and Outcomes in Patients with Inflammatory Bowel Disease with Adalimumab Treatment. A Real-world Prospective Study},
  journal = {Journal of Gastrointestinal and Liver Diseases},
  year = {2022},
  volume = {31},
  number = {4},
  pages = {403--410},
  doi = {10.15403/jgld-4375}
}
Kostenlos starten →